Background RSV-associated acute respiratory infections (ARI), particularly lower respiratory
tract diseases (LRTD), present a significant disease burden in older adults. Currently, there …

Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions
are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness …

Background Respiratory syncytial virus (RSV) is an important cause of disease in older
adults and is associated with high morbidity and mortality, especially in those with high-risk …

Background RSV causes respiratory infections that can lead to serious respiratory
complications in older adults (OA). Presently, there is no approved vaccine to prevent RSV …

Background RSV causes significant disease burden in older adults, since reinfections are
common and may lead to severe disease presentations while only supportive treatment is …

1Papi A, et al; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein
vaccine in older adults. N Engl J Med. 2023; 388 (7): 595-608 2Walsh EE, et al; RENOIR …

Background Respiratory syncytial virus (RSV) is an important cause of acute respiratory
infection, lower respiratory tract disease, clinical complications, and death in older adults …

Background Respiratory syncytial virus (RSV) is a contagious pathogen causing acute
respiratory infections (ARIs). Symptoms range from mild upper respiratory tract infections to …

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine
(RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 …

Background Previous phase 3 studies showed that the AS01 E-adjuvanted respiratory
syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is …